INTRODUCTIONSurgery is the mainstay of curative‐intent treatment for retroperitoneal sarcoma (RPS). Given that these tumors typically grow to a considerable size prior to detection and can often involve multiple organs, definitive surgery frequently requires a complex, multivisceral resection. In order to devise tailored treatment strategies for individual patients and to counsel them accordingly, sarcoma surgeons must be able to appreciate the anticipated morbidity of a proposed procedure. The literature surrounding the short‐ and long‐term outcomes following resection of RPS is scant and limited by considerable heterogeneity in patient populations and surgical approach. Accepting these limitations, the data available to guide decision‐making are reviewed here.EXTENT OF SURGERY AND SHORT‐TERM MORBIDITYOver the past decade, there has been a paradigm shift toward a radical surgical approach to RPS. In 2009, two European centers published data suggesting improved oncologic outcomes with liberal en bloc resection of organs adhering to, but not necessarily invaded by, RPS. Gronchi et al reported significantly reduced local recurrence rates with radical resection compared to an historical cohort who underwent marginal excision at the same institution. With longer follow‐up, this improvement in local control was found to be associated with improved overall survival. The evolution toward more radical resection
Journal of Surgical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera